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Inhibitory Effects of Non-steroidal Anti-inflammatory
Drugs on Human Myeloperoxidase
C. N. THERON, SUSAN LUBBE, A. VAN ZYL
SUMMARY
Myeloperoxidase with an A420!280 ratio of 0,48 was pre-
pared from normal human leucocytes. This partially purified
preparation catalysed guaiacol oxidation, iodination of
bovine serum albumin and de-iodination of 1251-thyroxine.
Non-steroidal anti-inflammatory drugs (naproxen, indo-
methacin and f1ufenamic acid) showed a significant inhibi-
tory effect on myeloperoxidase-catalysed iodination at
concentrations of 10"4M and higher. Guaiacol also inhibited
myeloperoxidase-catalysed iodination, and its iodination
inhibition curve was nearly identical to that obtained with
the anti-inflammatory drugs.
At concentrations between 10"'M and 10"M the anti-
inflammatory drugs had very little or no effect on thy-
roxine de-iodination. Flufenamic acid and indomethacin,
however, inhibited de-iodination significantly at a concen-
tration of 10'M.
It is postulated that non-steroidal anti-inflammatory
drugs may inhibit myeloperoxidase-catalysed protein iodi-
nation by acting as oxidizable cofactors which compete
with other oxidiza'ble substrates for oxidants formed by
the peroxidase-hydrogen peroxide complex. In view of this
and because the myeloperoxidase-hydrogen peroxide
system may be involved in inflammatory tissue damage,
the possibility should be considered that the action of
non-steroidal anti-inflammatory drugs is at least partly
attributable to a radical scavenging effect or to seque-
stration of oxidants.
S. Air. med. J., 56, 670 (1979).
Current ideas about the mode of action of non-steroidal
anti-inflammatory drugs are based mainly on evidence that
they inhibit prostaglandin synthesis. There is, however,
evidence that highly reactive free radicals may also play
an important role in inflammatory diseases.'" In the latter
context it is important to take a closer look at the func-
tion of peroxidases, and more particularly the myelo-
peroxidase-hydrogen peroxide system in neutrophils.
Myeloperoxidase, hydrogen peroxide and an oxidizable
cofactor such as haJide combine to form a potent micro-
bicidal system which kills micro-organisms after they have
been ingested by neutrophils. The system probably exerts
its microbicidal effect by halogenating essential macro-
molecules on the invading organism. But whatever the
precise nature of its microbicidal action may be, it seems
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clear that the myeloperoxidase system fulfiJs an essential
function in normal host defences against infections (for
review see Klebanotr).
Myeloperoxidase may also be implicated in tissue
damage associated with inflammatory processes. This
notion is supported by evidence that the myeloperoxidase
system is toxic to normal mammalian cells and to tumour
cells.'" Furthermore, both myeloperoxidase and hydrogen
peroxide are released into the extracellular fluid by neutro-
phils during phagocytosis or immune stimulation:"
If the microbicidal functions of leucocytes are involved
in inflammatory processes - and this seems very likely -
it would obviously be important to find out whether anti-
inflammatory drugs affect such functions. There is in fact
some evidence that anti-inflammatory drugs, notably phen-
ylbutazone, inhibit the bactericidal capacity of neutro-
philsY' Olofsson and Olssonll showed that phenylbutazone
and sodium salicylate inhibit myeloperoxidase-catalysed
iodination of yeast cells in vitro, and suggested that this
may explain the reduced bacterial killing capacity of
neutrophils exposed to phenylbutazone.
Van Zyl and Louw" showed that non-steroidal anti-
inflammatory drugs inhibit iodination of bovine serum
albumin (BSA) catalysed by purified thyroid peroxidase,
lactoperoxidase and chloroperoxidase. Van Zyl et al.13
also demonstrated an inhibitory effect of some anti-inflam-
matory drugs on BSA iodination catalysed by sonicated
leucocytes. They ascribed this to an effect on the catalytic
activity of myeloperoxidase.
To extend our previous investigations we prepared
myeloperoxidase from normal human leucocytes. In this
article we describe the effects of three non-steroidal anti-
inflammatory drugs on myeloperoxidase-catalysed BSA
iodination and thyroxine de-iodination.
MATERIALS AND METHODS
Human Leucocytes
Fresh, heparinized human blood from healthy donors
was obtained from the Western Province Blood Transfu-
sion Service. Leucocytes were isolated essentially as
described by Olsson et al." The isolated leucocytes were
suspended in a small volume of balanced saIt solution
and kept frozen in liquid nitrogen until further use. The
balanced salt solution contained 6,8 g NaCl, 0,4 g KCl,
0,2 g CaC\', 0,1 g MgS04, 0,125 g NaH,PO., 2,2 g NaHC03
and 0,1 g glucose made up to 1 litre with distilled water.
Solubilization of Myeloperoxidase
Frozen leucocytes obtained from 6 litres of blood were
thawed and the sllspension (150 ml) was dialysed overnight
at 4°C against 0,5% Triton X-100 in 0,05M phosphate
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buffer (pH 6,3). Dialysis caused complete lysis of con-
taminating red blood cells. Haemoglobin was removed by
centrifuging the leucocyte suspension at 35 000 g for 30
minlltes and discarding the clear red supernatant.
The olive green pellets were suspended in 40 ml 0,5M
NaCl, 0, IM phosphate buffer (pH 5,8), and homogenized
with an Ultra Turrax homogenizer (two 30-second bursts
at maximum speed). The homogenate was then divided
into I - 2 ml aliquots and the leucocytes were further dis-
rupted by ultrasonication with an MSE ultrasonicator.
Homogenates were cooled by keeping the tubes immersed
in crushed ice.
After sonication the leucocyte homogenate was centri-
fuged at 105000 g for 1 hour at 5°C. This resulted in a
clear green supernatant with high peroxidase activity and
white pellets without appreciable peroxidase activity. The
pellets were discarded and the soluble myeloperoxidase in
the supernatant was further purified.
Purification of Myeloperoxidase
To purify myeloperoxidase we used a two-step method
consisting of gel filtration followed by ion exchange
chromatography.
Gel filtration: The solution of crude myeloperoxidase
wa concentrated by pressure dialysis to a volume of 25
ml and applied to a 80 x 3 cm Sepharose 4B column equi-
librated with 0,5M aCl and O,lM phospha;e buffer (pH
6,0). Protein fractions (6 ml) were eluted with the same
buffer at a flow rate of 36 ml per hour. Absorbance at
260, 280 and 420 nm was measured spectrophotometri-
cally for each fraction and peroxidase activity was esti-
mated by means of a guaiacol assay.
Ion exchange chromatograph)' was performed essentially
as described by Zglicynski et al." The myeloperoxidase-
comaining fractions eluted from the Sepharose column
were pooled and dialysed overnight at 4°C against 0,1 M
phosphate buffer (pH 6,0). It was then applied to a
column containing 10 g Cellex-CM (Biorad) equilibrated
with 0,1 M phosphate buffer (pH 6,0). Protein was eluted
with a 500 ml linear 0, I - 0,4M NaCl gradient in a 0, IM
phosphate buffer gradient (pH 6,0 - 7,8). Absorbance
measurements and estimations of myeloperoxidase activity
were done on each fraction.
Guaiacol Assay for Peroxidase Activity
The reagent mixture for the guaiacol assay consisted of
100 j.tl 0,089M guaiacol (Merck) and 200 iJ.ll 0,5°~ bovine
serum albumin (Pentex) dissolved in O,lM phosphate
buffer (pH 7,0). To this was added a small volume of
myeloperoxidase-containing fractions and O,lM phosphate
buffer to give a final volume of 2,0 m!. To start the
reaction, 20 ,ul O,OIM hydrogen peroxide was added and
the reagents rapidly mixed on a vortex stirrer. The mixture
was then quickly transferred to a cuvette and the change
in absorbance at 470 nm measured spectrophotometrically
0,5 minute after adding the hydrogen peroxide.
Iodination Experiments
Myeloperoxida e-catalysed protein iodination was stu-
died at pH 7,0 in the presence of laC!. The reaction
mixrure consisted of the following reagents (final concen-
trations given in brackets): sodium phosphate buffer
(O,IM, pH 7,0); BSA (5 mg/ml); Kl (lO-'lM); carrier-
free '''1 (0,5 j.tCi); NaCl (0,1 M); purified myeloperoxidase
(0,8 jLg/ml); and H2O, (lO··M). All the reagems were
dissolved in O,IM phosphate buffer (pH 7,0). When a
hydrogen peroxide-generating sy tern was required, glucose
and glucose oxidase were added, as described by Van Zyl
and Louw."
Each anti-inflammatory drug was dissolved in 1,0M
tris. From this stock olution a series of dilutions
were made in 0, IM phosphate buffer (pH 7,0) to give
final drug concentrations ranging from 10-' to 10-- in the
iodination reaction mixture. For each tube containing a
drug, an appropriate reagent control, consisting of 1,OM
tris diluted as for the corresponding drug dilution,
was included. The final volume of each reaction mixture
(after adding the drug or reagent control) was 500 jL!.
Appropriate blanks, which contained all reagents except
myeloperoxidase, were included for each experiment.
Reactions were started by adding hydrogen peroxide and
rapidly mixing the components on a vortex stirrer. Tubes
were then incubated at 37°C for 20 minutes. At the end
of incubation a 25 j.tl ample of each reaction mixture
was chromatographed on paper in butanol-acetic acid-
water to separate unbound iodide from protein-bound
iodide. The radioactivity in each fraction was then mea-
sured with an Autogamma spectrometer and the percen-
tage .BSA iodination calculated from the total counts of
bound and unbound '''1.''
Thyroxine De-iodination
Protocols for myeloperoxidase-catalysed de-iodination
were essentially similar to those for iodination. The only
differences were that the final reaction volume was 250
JLI and that 2 p.Ci '''I-thyroxine replaced BSA, KI and
'''I. Paper chromatography wa again used to separate
radiolabeHed components.
Anti·inflammatory Drugs
Flufenamic acid (Arlef) was obtained from Parke Davis,
Johannesburg, naproxen Taprosyn) from Syntex Labora-
tories, Palo Alto, California, and indomethacin (lndocid)
from MSD, Johannesburg.
RESULTS
Properties of Myeloperoxidase
Gel filtration and ion exchange chromatography (Figs
1 and 2) yielded a clear, pale green enzyme preparation
which catalysed guaiacol oxidation, protein iodination and
thyroxine de-iodination in the presence of hydrogen
peroxide. Enzyme preparation obtained during succe sive
srages of purification howed a progressive increa e in
specific activity for classic peroxidase-catalysed reaction
(guaiacol oxidation) and a concomitant increase in the 420/
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Fig. I. Elution profile of protein fractions after separation
of crude soluble myeloperoxidase on Sepharose 4B.
280 run absorbance ratio (Table I). The two fractions
with the hjghest specific peroxidase activity had 420/280
nm absorbance ratjos of 0,48 and 0,37. A value of 0,80
for this ratio in the case of myeloperoxidase is generally
accepted as an indication of the absence of contaminating
proteins.H."
To determine the smallest amount of enzyme needed.
for effective iodination of BSA, we studied the effect of
myeloperoxidase concentration on iodination. The results
are shown in Fig. 3.
Effect of Myeloperoxidase Concentration on
Iodination
._.pH 6,0
75 .- -. pH 7,0
However, on the basis of its A420/280 ratio and specific
activity, we considered the preparatjon to be satisfactory
for preliminary studies of myeloperoxidase-catalysed iodi-
nation and de-iodination.
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Fig. 2. Elution profile after ion exchange chromatography
on Cellex-CM of pooled peroxidase-containing fractions
from Sepharose 4B.
The two purest fractions of myeloperoxidase together
contained only 0,56 mg protein. Thjs was a disappointingly
Iow yield in comparison with that obtained by others."
At pH 6,0 the maximum efficiency of iodination was
66%. This was achieved at a myeloperoxidase concentra-
tion of 5 jLg/ml reaction mixture. However, near maxi-
mum efficiency was already obtained with an enzyme
concentration of 1 .....g/mL This curve agrees very closely
with the one obtained by Dubin and Silberring'· under
nearly similar conditions.
At pH 7,0 the maximum efficiency of iodination was
only 50% but near maximum efficiency was obtained with
an enzyme concentration of 0,8 .....g/mL Since a linear rela-
tionship between enzyme concentration and iodination
was observed up to a concentration of 0,8 .....g/ml, we
used this concentration for all further iodination and de-
iodination experiments described here.
115 I.Il 15 Z.1l Z5 3.1l 3.5 4.0 4,5 5.0
,'I~elopero\idase Cunc. (u:;fml reaclion mixture)
Fig. 3. Percentage BSA iodination obtained with different
concentrations of purified myeloperoxidase at pH 6,0 and
pH 7,0. The reaction mixture (total volume 500 1'1)
contained BSA (5 mg/ml); KI (l0-'M); carrier-free '''I
(0,5 .uCi); aCI (0,1M); H,O, (lO-'M) and different
amounts of purified myeloperoxidase. The reagents were
dissolved in O,IM phosphate buffer pH 6,0 or pH 7,0.
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TABLE I. ABSORBANCE RATIO (A420/280) AND SPECIFIC ACTIVITY OF MYELOPEROXIDASE AT DIFFERENT
STAGES OF PURIFICATION
Purification stage
Leucocyte homogenate
Crude soluble myeloperoxidase
Gel filtration
Ion exchange chromatography
A42D/28D ratio
0,026
0,21
0,48
Specific activity for
guaiacol oxidation
(M7D/D,S min/mg
protein)
1,57
15,75
29,6
262,5
Increase in specific
activity
10-fold
20-fold
168-fold
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Effect of Anti-inflammatory Drugs and Guaiacol
on Iodination and De-iodination
Tile effects of anti-inflammatory drugs on myeloperoxi-
dase-catalysed BSA iodination and '>SI-thyroxine de-iodina-
tion are shown in Figs 4 - 6. Briefly stated, these effects
were as follows:
All three drugs inhibited BSA iodination at pH 7,0 in
the presence of added hydrogen peroxide (lO....M) or a
hydrogen peroxide-generating system (Figs 4 - 5). The inhi-
bitory effects of the three drugs on iodination did not
differ greatly, although naproxen was slightly less effec-
tive than indomethacin and flufenamic acid in the pre-
sence of a hydrogen peroxide-generating system (Fig. 5).
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In contrast to their inhibitory effect on BSA iodination
the anti-inflammatory drugs had very little or no effect on
the de-iodination of ':SI -thyroxine at low drug concentra-
tions. At IQ-'M flufenamic acid and indomethacin inhibi-
ted de-iodination significantly.
Guaiacol, a classic oxidizable cofactor for peroxidases,
showed an inhibitory effect on BSA iodination which
was nearly identical to that observed for the anti-inflam-
matory drugs (Fig_ 7).
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Fig. 5. Ellects of non-steroidal anti-inflammatory drugs
on myeloperoxidase-catalysed BSA iodination in the pre-
sence of a H,O,-generating system. Tile reaction mixture
was as described in Fig. 4, except that H,O, was replaced
by a H"O,-generating system consisting of 0,5 pg glucose
oxidase and 5 mg glucose.
Fig. 4. Effects of non-steroidal anti-inflammatory drugs on
myeloperoxidase-catalysed BSA iodination in the presence
of added H,o.,. The reaction mixture (total volume 500
pi) contained: phosphate bufier (O,lM, pH 7,0); BSA
(5 mg/ml); KI (10....M); carrier-free '''''. (0,5 pCi); NaCI
(O,IM); RO, (10-"M); purified myeloperoxidase (0,8 pg/
ml) and different amounts of anti-inflammatory drugs.
The inhibition of iodination was dose-dependent and
we observed significant inhibition only at concentrations
greater than IQ-'M for all three drugs (Fig. 5). At lO-4M
and in the presence of a hydrogen peroxide-generating
system flufenamic acid and indomethacin caused about
55, 60% inhibition, while naproxen caused about 30%
inhibition at this concentration; nearly 100% inhibition
was achieved with drug concentrations of IQ-'M.
DISCUSSION
We have shown that indomethacin, flufenamic acid and
naproxen inhibit myeloperoxidase-cataIysed protein
iodination. These findings extend and confirm certain
earlier observations. Olofsson and Olsson," for example,
demonstrated that phenylbutazone and sodium salicylate
inhibit in vitro iodination of yeast cells in a system con-
taining purified myeloperoxidase. As early as 1973 Saeed
and Warren" provided evidence that several non-steroidal
anti-inflammatory drugs, including indomethacin, inhibit
horseradish peroxidase-catalysed oxidation of O-diarusi-
dine. More recently, Van Zyl and Louw" showed that non-
steroidal anti-inflammatory drugs had an inhibitory effect
on several purified peroxidases. Other very recent experi-
ments in our unit indicate that anti-inflammatory drugs
6
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inhibit in viTro iodination catalysed by sonicated human
leucocytes." This was ascribed to an inhjbitory effect on
myeloperoxidase, an a9sumption which our present obser-
vations support.
o
o
,
Guaiacol Concentration (Molar)
Concentration of Anti - inflammatory Drugs (Molar)
Fig. 6. Effects of non-steroidal anti-inJIammatol)' drugs
on m)'eloperoxidase-catalysed de-iodination of ''''I_thy_
roxine. The reaction mixtur-e (total volume 250 pI) con-
tained: phosphate buffer (O,lM, pH 7,0); ''''I-thyroxine
(2 )LCi); NaCI (0,1M); H,O, (l0-'M); purified myelo-
peroxidase (0,8 )Lg/ml) and different amounts of anti-
inffammatof)' drugs.
Because the myeloperoxidase system plays an important
role in the antimicrobial functions of neutrophils, the
question arises whether in vitro inhibition of this system
by anti-inflammatory agents has any clinical significance.
Would long-term treatment with these drugs, for example,
weaken normal host defences against infection?
On the weight of existing evidence the answer to this
question would most probably have to be no. As Kleba-
noff' pointed out, inhibition of myeloperoxidase-catalysed
halogenation doe!> not necessarily imply a discernible
decrease in the bactericidal capacity of leucocytes in vivo.
In the intact neutrophil other microbicidal substances
(e.g. hydrogen peroxide or superoxide anion) may com-
pensate for decreased myeloperoxidase activity. Further-
more, we are not aware of clinical evidence that therapy
with non-steroidal anti-inflammatory agents may cause an
increased susceptibility to infection. FinaJly, it should be
borne in mind that we observed near 100% inhibition
only at non-therapeutic drug concentrations.
Fig. 7. Effect of different concentrations of guaiacol on
myeloperoxidase-catalysed RSA iodination in the presence
of added H,O,. The reaction mixture (total volume 500
)LI) contained: phO'iphate buffer (O,IM, pH 7,0); RSA
(5 mg/mt); KJ (10~M); carrier-free =1 (0,5 )LCi); NaCI
(0,1M); 0,0, (l0-'M); purified myeloperoxidase (0,8 ~/
mt) and different amounts of guaiacol.
Despite these considerations we feel that this question
should be approached with an open mind. Strauss et al.'
found that phenylbutazone inhibited both engulfment and
kiJling of Escherichia coli by peritoneal leucocytes in
guinea-pigs. One should also bear in mind that certain
clinical syndromes, characterized by recurrent infections,
are associated with defective bactericidal functions of
neutrophils. Examples are chronic granulomatous disease
in children, Chediak-Higashi syndrome and congenital or
acquired myeloperoxidase deficiency. (For a review of this
topic see Quie."') It is conceivable that in these instances
long-term treatment with drugs which inhibit the myelo-
peroxidase system may further weaken the already de-
pressed antibacterial capacity of leucocytes.
Our observation that anti-inflammatory drugs had a
much greater inhibitory effect on protein iodination than
on thyroxine de-iodination, also applies to the peroxi-
dases investigated by Van Zyl and Louw.12 The differences
between the inhibitory effects on the two reactions have
an important bearing on the mechanism of inhibition.
Klebanoff and Hamon" divide peroxidase inhibitors
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into two groups. The first group includes substances such
as azide and cyanide which form complexes with the
haem iron of peroxidase and inactivate the enzyme
directly. The second group inhibits peroxidase-catalysed
reactions indirectly by competing with other oxidizable
cofactors for the available hydrogen peroxide. Members
of the second group may inhibit some peroxidase-catalysed
reactions and not others, depending on their relative
oxidation-reduction potentials.
The differences which we observed between inhibition
of iodination and of de-iodination can be explained by
the assumption that the non-steroidal anti-inflammatory
drugs belong to the second group of peroxidase inhibitors,
defined above, i.e. they act as competitive cofactors for
peroxidases. The fact that guaiacol, a classic peroxidase
cofactor, produced an iodination inhibition curve which
virtually matched that obtained with the anti-inflammatory
drugs, strongly supports this assumption.
To explain how anti-inflammatory agents might inhibit
iodination, it is necessary to consider the possible mecha-
nisms by which the myeloperoxidase-hydrogen peroxide
system iodinates proteins. One probable mechanism which
has been postulated involves the release of hypocWorite
and hydroxide when the myeloperoxidase-hydrogen
peroxide complex reacts with chloride. Hypochlorite is
very reactive and a potent oxidant. It can react with amino
acids to produce chloramines, which by rearrangement
will result in oxidative de-amination of the amino acids.
Hypochlorite can also chlorinate phenolic compounds or
oxidize iodide to yield molecular iodine (I,). I, is of course
also. a strong oxidant and bactericidal substance which
easily iodinates tyrosine and histidine in proteins. When
the iodide concentration is low conditions would be
appropriate for iodination of phenols (for review see
Morrison and Schonbaumj. Non-steroidal anti-inflam-
matory drugs may act as inhibitors of iodination by
scavenging the oxidants which convert 1- to I" or they
may compete with tyrosine for I" i.e. they may be iodina-
ted.
The possibility that non-steroidal anti-inflammatory
drugs may act as competitive cofactors which sequester
(scavenge) oxidants released during peroxidatic reactions,
open an interesting field for speculation.
As early as 1970 Otomo and Fuhira (quoted by Saeed
and Warren") studied lipid peroxidation induced by
radiation and hydrogen peroxide. They suggested that
anti-inflammatory drugs may act by scavenging free radi-
cals or peroxides. More recently, Fridovich1 " has accumu-
lated evidence that highly toxic oxygen radicals such as
superoxide (On and the hydroxyl radical (OH') may be
important mediators of inflammatory processes.
Predominant ideas about the mode of action of non-
steroidal anti-inflammatory drugs are still focused on
inhibition of prostaglandin synthesis. One of the steps of
prostaglandin synthesis involves the peroxidatic conver-
sion of PGG, to PGH,. Very recent work has shown that
this reaction releases an extremely potent oxidant which
may play a key role in the pathogenesis of inflammatory
diseases.'·'" Furthermore, the anti-inflammatory action of
a new compound, MK-447, correlates well with the
ability of this compound and other radical scavengers to
sequester this destructive oxygen moiety." While our
observations do not provide direct evidence that non-
steroidal anti-inflammatory agents act as radical scaven-
gers, they do fit such a concept. A more rigorous and
direct attempt to test this hypothesis may well be worth
while.
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